Billion Dollar Genetic Disease Stock Crashes, Loses 90% Value As Lead Drug Fails In Trial

Benzinga_recent_news12-12

Rezolute Inc. (NASDAQ:RZLT) stock is plunging on Thursday, with a session volume of 82.25 million compared to the average volume of 1.597 million as per data from Benzinga Pro. The company on Thursday...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590433905?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/11/Female-Scientist-Working-In-The-Lab--She.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-12-12 01:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590433905","market":"sh","top_or_hot":-1,"title":"Billion Dollar Genetic Disease Stock Crashes, Loses 90% Value As Lead Drug Fails In Trial","media":"Benzinga_recent_news","content":"<div>\n<p>Rezolute Inc. (NASDAQ:RZLT) stock is plunging on Thursday, with a session volume of 82.25 million compared to the average volume of 1.597 million as per data from Benzinga Pro.\nThe company on Thursday...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49341806/billion-dollar-genetic-disease-stock-crashes-loses-90-value-as-lead-drug-fails-in-trial\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Billion Dollar Genetic Disease Stock Crashes, Loses 90% Value As Lead Drug Fails In Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBillion Dollar Genetic Disease Stock Crashes, Loses 90% Value As Lead Drug Fails In Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-12 01:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/25/12/49341806/billion-dollar-genetic-disease-stock-crashes-loses-90-value-as-lead-drug-fails-in-trial><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Rezolute Inc. (NASDAQ:RZLT) stock is plunging on Thursday, with a session volume of 82.25 million compared to the average volume of 1.597 million as per data from Benzinga Pro.\nThe company on Thursday...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49341806/billion-dollar-genetic-disease-stock-crashes-loses-90-value-as-lead-drug-fails-in-trial\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2125154935.USD","symbol_name":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/25/12/49341806/billion-dollar-genetic-disease-stock-crashes-loses-90-value-as-lead-drug-fails-in-trial","article_id":"2590433905","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/11/Female-Scientist-Working-In-The-Lab--She.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49341806/billion-dollar-genetic-disease-stock-crashes-loses-90-value-as-lead-drug-fails-in-trial","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2590433905","pubTimestamp":1765474380,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Rezolute sinks after its Phase 3 congenital hyperinsulinism trial showed no statistically significant benefit for ersodetug despite favorable safety data.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","HI":"希伦布兰德","RZLT":"Rezolute, Inc.","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","BK4139":"生物科技","BK4161":"工业机械","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC"},"translate_title":"由于主要药物试验失败，价值数十亿美元的遗传病股票暴跌，价值损失90%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HI":1,"RZLT":1},"content_text":"Rezolute Inc. (NASDAQ:RZLT) stock is plunging on Thursday, with a session volume of 82.25 million compared to the average volume of 1.597 million as per data from Benzinga Pro.\nThe company on Thursday released topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism (HI).\nCongenital Hyperinsulinism is a rare genetic disorder causing the pancreas to secrete too much insulin, leading to dangerously low blood sugar (hypoglycemia) in infants and children.\nAlso Read: Rezolute ‘Thrilled’ With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December\nThe study did not meet its primary endpoint, which assessed the change in the average weekly hypoglycemia events by self-monitored blood glucose.\nThere was an approximate 45% reduction in hypoglycemia events observed at the top ersodetug dose (10 mg/kg), which was not statistically significant compared to the placebo group, which experienced a 40% improvement.\nFurthermore, the study did not meet its key secondary endpoint, which assessed the change in average daily percent time in hypoglycemia by continuous glucose monitoring (CGM).\nAt the 10 mg/kg dose of ersodetug, an approximate 25% reduction in time in hypoglycemia was observed, which was not statistically significant compared to the placebo, which increased by approximately 5%.\nAt the study dose regimens of 5 and 10 mg/kg administered every other week for three doses, followed by every 4 weeks over the remainder of the 24-week treatment duration, ersodetug target drug concentrations were achieved across all age groups studied.\nSafety observations from the study were generally favorable and, in the opinion of the company, support safe use of ersodetug in pediatric and adult patients.\nTwo of the study participants experienced serious hypersensitivity reactions, which led to early discontinuation of the study drug.\nThe Phase 3 upLIFT study for tumor HI is ongoing, with topline results expected in the second half of 2026.\nRZLT Price Action: Rezolute shares were down 88.76% at $1.23 at the time of publication on Thursday. The stock is trading at a new 52-week low, according to Benzinga Pro data.\nRead Next:\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590433905","isCrawlerRequest":true}